| Title |
|
|
|
Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy
| |
| Author |
|
|
|
| |
| Institution/Organisation |
|
|
|
EORTC Lymphoma Grp
| |
| Abstract |
|
|
|
| Since1964, the EORTC Lymphoma Group has conducted nine consecutive randomized phase III trials on early-stage Hodgkin lymphoma aimed at increasing efficacy while decreasing short- and long-term toxicities. Event-free and overall survival significantly improved from about 50% and 70%, respectively, in the early years to over 80% and 90%, respectively, more recently. Identification of prognostic subgroups appeared to be a successful method to tailor treatment strategies. Radiotherapy fields have become more restricted whereas chemotherapy has become standard. Early PET-CT has been introduced to investigate the possibility of treatment adaptation. Longitudinal quality-of-life assessment has become an integral part of our studies. An ongoing study focuses on the rehabilitation and quality of long-term survival in all 6658 Hodgkin lymphoma patients treated in EORTC trials since the earliest beginning. In advanced stages overall outcome has improved as well with 10-year survival rates of over 75%. (C) 2012 European Organisation for Research and Treatment of Cancer. All rights reserved. |
| |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
European journal of cancer : supplements. - Amsterdam, 1990, currens | |
| Publication |
|
|
|
Amsterdam : 2012
| |
| ISSN |
|
|
|
1359-6349 [print]
1878-1217 [online]
| |
| Volume/pages |
|
|
|
10:1(2012), p. 105-111
| |
| ISI |
|
|
|
000302130800017
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (open access) |
|
|
| | |
|